Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 10, 2001, Pages 2755-2764

  Ince, D ^a   Hooper, D C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 (3 METHYL 1 PIPERAZINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; DESMETHOXYFLUOROQUINOLONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; ISP 794; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CELL KILLING; ENZYME INHIBITION; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GENE FREQUENCY; GENES, BACTERIAL; GENOTYPE; LINKAGE (GENETICS); MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; STAPHYLOCOCCUS AUREUS;

EID: 0034812537     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.10.2755-2764.2001     Document Type: Article

References (55)

1. Structure and mechanism of DNA topoisomerase II
2. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin
3. Crystal structure of the breakage-reunion domain of DNA gyrase
4. DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage
5. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118
6. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program
7. Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance
8. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
9. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
10. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
11. Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity
12. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity
13. Primary targets of fluoroquinolones in Streptococcus pneumoniae
14. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus
15. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
16. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro
17. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents
18. Mechanisms of quinolone resistance
19. In vitro and in vivo antibacterial activities of AM-1155: A new 6-fluoro-8-methoxy quinolone
20. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: Novel mutations suggest novel drug-target interactions
21. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
22. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America
23. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus
24. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage
25. Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in Staphylococcus aureus
26. Transformation of chromosomal and plasmid characters in Staphylococcus aureus
27. Gatifloxacin activity against quinolone-resistant gyrase: Allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group
28. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA grase A and B proteins
29. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates
30. Quinolone resistance mediated by norA: Physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome
31. Quinolone resistance mutations in topoisomerase IV: Relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus
32. Genetic systems in staphylococci
33. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States
34. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
35. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
36. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones
37. Gatifloxacin
38. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
39. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC
40. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria
41. Confirmation of protoplast fusion-derived linkages in Staphylococcus aureus by transformation with protoplast DNA
42. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus
43. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus
44. Emerging resistance to fluoroquinolones in staphylococci: An alert
45. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus
46. Parc and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
47. In vitro antibacterial activity of AM-1155: A novel 6-fluoro-8-methoxy quinolone
48. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex
49. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose
50. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus
51. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
52. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8 methoxyl group on survival in liquid media and in human macrophages
53. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones
54. DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance
55. Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinolone-resistant mutations